New blood test could prevent dangerous delays in preeclampsia deliveries
NCT ID NCT07665112
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a blood test measuring the sFlt-1/PlGF ratio can help doctors decide the best time to deliver babies in women with severe early-onset preeclampsia. The trial will include 386 pregnant women between 30 and 34 weeks of gestation. Half will have delivery timing guided by the test results, while the other half will receive standard care. The goal is to reduce serious complications for both mothers and newborns.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sFlt-1/PlGF ratio blood test
What this could lead to
If successful, this blood test could help doctors decide the safest time to deliver in severe preeclampsia, reducing serious complications for both mother and baby.
What could go wrong
This is an early-stage trial with 386 participants, so results may not apply to all cases. The test may not improve outcomes as hoped, and timing decisions still carry risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE PREECLAMPSIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
c/ Sabino Arana, 1. 08028 Barcelona
Barcelona, Barcelona, 08028, Spain
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact